Insights Into the Emerging Entity of HER2‐Low Breast Cancer
Open Access
- 1 January 2024
- journal article
- review article
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 2853007
Abstract
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.Keywords
This publication has 56 references indexed in Scilit:
- Comprehensive characterization of HER2-low breast cancers: implications in prognosis and treatmentEBioMedicine, 2023
- Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 ExpressionClinical Breast Cancer, 2023
- The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancerClinical and Translational Oncology, 2022
- Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancerThe Breast, 2022
- Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast CancerClinical Pharmacology & Therapeutics, 2022
- Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapyEuropean Journal of Cancer, 2022
- Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancerEuropean Journal of Cancer, 2022
- Evolution of low HER2 expression between early and advanced-stage breast cancerEuropean Journal of Cancer, 2022
- Prognostic impact of HER2-low expression in hormone receptor positive early breast cancerThe Breast, 2021
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyStem Cells, 1998